The NM_000152.5:c.1802C>G variant in GAA is a missense variant predicted to cause substitution of serine serine by tryptophan at amino acid 601 (p.Ser601Trp). The highest population minor allele frequency in gnomAD v4.1.0 is 0.0000008475 (1/1179962 alleles) in the European, non-Finnish population, which is lower than the ClinGen Lysosomal Diseases VCEP’s threshold for PM2_Supporting (<0.001), meeting this criterion (PM2_supporting). The computational predictor REVEL gives a score of 0.964 which is above the threshold of 0.7, evidence that correlates with impact to GAA function (PP3). When expressed in COS-7 cells, the variant resulted in <2% wild type activity indicating that this variant may impact protein function (PMID: 19862843) (PS3_supporting). Another missense variant (c.1802C>T, p.Ser601Leu) in the same codon has been classified as pathogenic for Pompe disease by the ClinGen Lysosomal Diseases VCEP (ClinVar Variation ID: 194154; Accession: SCV002032130.1) (PM5). This variant has been detected in at least 11 individuals with Pompe disease. Of those individuals, 9 were compound heterozygous for the variant and the c.-32-13T>G variant (classified as pathogenic by the ClinGen LD VCEP). One individual was compound heterozygous for the variant and the c.1935C>A (p.Asp645Glu) variant (classified as pathogenic by the ClinGen LD VCEP). One individual was compound heterozygous for the variant and c.2800-1G>C (not classified by the ClinGen LD VCEP). Zero individuals were homozygous for the variant. (PM3). At least 3 patients with this variant had documented GAA deficiency with <10% of normal mean control level of GAA activity in leukocytes, lymphocytes, or muscle samples (PMID: 17056254, 22958975, 24158270) and 2 patients were reported to be on enzyme replacement therapy for Pompe disease (PMID: 22081099, 29422078). This meets the criteria for PP4_moderate. There is a ClinVar entry for this variant (Variation ID: 501793). In summary, this variant meets the criteria to be classified as Likely Pathogenic for Pompe disease. GAA-specific ACMG/AMP criteria met, based on the specifications of the ClinGen Lysosomal Diseases VCEP (Specifications Version 2.0): PP4_moderate, PM3, PM5, PP3, PM2_supporting, PS3_supporting. (Classification approved by the ClinGen Lysosomal Diseases Variant Curation Expert Panel on May 20, 2025)